The Q3 2014 earnings report for large cap toy stock Mattel, Inc (NASDAQ: MAT), a potential peer of mid cap�Hasbro, Inc (NASDAQ: HAS) and small cap JAKKS Pacific, Inc (NASDAQ: JAKK), is scheduled for before the market opens on Thursday (October 16th). Aside from the Mattel, Inc earnings report, it should be said that Hasbro, Inc will report Q3 2014 earnings on October 20th (Next Monday)�before the market opens while�JAKKS Pacific, Inc will report Q3 2014 earnings before the market opens on October 23rd (Thursday). Mattel, Inc, like other toy stocks, has struggled to remain relevant in an age when many kids prefer to play video, mobile and computer games rather than with physical toys.
What Should You Watch Out for With the Mattel, Inc�Earnings Report?First, here is a quick recap of Mattel, Inc�� recent earnings history along with EPS estimate trends from the Yahoo! Finance analyst estimates page:
Best Services Companies For 2015: Jinzanghuang Tibet Pharmaceuticals Inc (JZHG)
Jinzanghuang Tibet Pharmaceuticals, Inc. distributes Tibetan pharmaceutical and nutraceutical products in the People�� Republic of China (PRC) through Leling Jinzanghuang Biotech Co., Ltd. (Leling JZH). The Company, through its wholly owned subsidiary, Tibet Medicine, Inc., owns 100% of Beijing Taibodekang Consulting Co., Ltd. (Beijing Taibodekang), a wholly foreign owned entity. Beijing Taibodekang had entered into four agreements with Leling Jinzanghuang Biotech Co., Ltd. (Leling Jinzanghuang) and with the equity owners in Leling Jinzanghuang. Collectively, the agreements provide Beijing Taibodekang exclusive control over the business of Leling Jinzanghuang. Leling Jinzanghuang engages in the distribution of the pharmaceutical and nutraceutical products that Tibetans have used for centuries to treat diseases and facilitate health. The distributed products are classified by Leling Jinzanghuang in three major categories: pharmaceuticals, therapeutic supplements, and dietary supplements.
The 13 Tibetan health products that Leling Jinzanghuang distributes are among those Tibetan medicines made with modern drug manufacturing techniques. The manufacturing equipment and techniques used by its supplier are certified under China�� national standards of Good Manufacturing Practice (GMP), and are in compliance with applicable regulations of the Chinese Food and Drug Administration (SFDA), which regulates both the pharmaceutical and the nutraceutical industries in China.
Ying Huang Tablet
Ying Huang Tablet is one the two pharmaceutical products marketed by Leling Jinzanghuang that been approved by SFDA. The effective ingredients in the Ying Huang Tablet are extracts from the honeysuckle and the Huangqin herb. It can be used to treat upper respiratory infections including pharyngitis, encephalitis and conjunctivitis. It can also be used to reduce inflammation and relieve pain.
San Qi Capsules
San Qi Capsules is a dietary supplements certified! by SFDA. San Qi Capsules lower blood lipid and cholesterol levels. Thus they can be used as a precautionary therapy to prevent cardiovascular diseases, including coronary heart disease, heart angina and stroke. In addition, the San Qi Capsules enhance immune system functions, which may help in the prevention of cancer.
Foshou Capsules
Foshou Capsules is a Tibetan nutraceutical. The effective ingredients, Xue Yu, Dongchong Xiacao, Fozhang, and Ginseng, are extracts of several plants and animals that are native to the Tibet Plateau.
Bai He Capsules
Bai He Capsules is a Tibetan dietary supplement. The effective ingredients consist of Baihe, Fozhang Ginseng and Himalayan purple jasmine. The Bai He Capsules are used to treat male erectile dysfunction and other sexual dysfunction problems.
The Company competes with Jingqiu Tibetan Medicine, Jinhe Tibetan Medicine and Tibetan Pharmaceutical Factory, Tibet Cheezheng Tibetan Medicine and Niemula Tibet Medicine.
Advisors' Opinion:- [By Peter Graham]
Small cap medical technology stock Sanomedics International Holdings (OTCMKTS: SIMH) recently completed financing and an acquisition while JinZangHuang Tibet Pharmaceuticals, Inc (OTCMKTS: JZHG) surged 48.28% on Friday. However, that�� only part of the story as one of these stocks has been the subject of paid promotions while the other has no new news for investors. So are either of these small cap stocks the cure for any portfolio pains you may be suffering from? Here is a quick reality check:
Top 10 Mid Cap Companies To Buy Right Now: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By Jayson Derrick]
AbbVie's (NYSE: ABBV) board of directors stated that it is reconsidering its recommendation to investors to approve its $55-billion takeover of Shire (NASDAQ: SHPG) due to proposed changes in U.S. tax rules that discourage takeovers of foreign firms as a tax-inversion. Shares of AbbVie gained 0.92 percent, closing at $54.63, while shares of Shire plunged 30.29 percent, closing at $170.49.
- [By Ben Levisohn]
Nevertheless, while we believe that the rejection vote is a setback to Valeant, we remain confident that Valeant will either ultimately succeed in its bid to acquire Allergan near-term or seek to consummate another transaction elsewhere. We note that thus far it does not appear that Allergan has much strategic wiggle room, having already been rebuffed by potential white knights such as Sanofi S.A. (SNY) and Johnson & Johnson (JNJ) and with little chance, in our view, of making a meaningful acquisition of its own, such as the purchase of Shire (SHPG).
- [By Johanna Bennett]
British drug maker Shire (SHPG) turned up its nose at the $46.5 billion offer by U.S. rival AbbVie (ABBV), in the latest move by a U.S. company to pursue a deal for a company with a lower tax rate. Simply put, Shire says the bid is to low and released ambitious new targets to more than double its annual sales to $10 billion by 2020.
What will it take to get the deal done?
Leerink analyst Jason Gerberry says AbbVie�� cash and stock offer is lacking in certain areas, namely the stock component is too high and there�� no contingent right value to reward Shire shareholders for pipeline assets that could pop down the road. He writes:
We believe the race for doing tax inversions will only accelerate, which works in SHPG�� favor, meaning demand for SHPG will be high and SHPG should seriously considering accepting a slightly higher offer that is more cash-rich and also allows shareholders to enjoy the potential upside if products like Premiplex or lifitegrast get approved. Next steps: ABBV will need to announce its firm intention to make another offer by 7/18. Other potential acquirers we could envision stepping in include AGN, PFE, and BMY.
AbbVie said Friday that it had made three cash-and-share proposals to the board of Shire, with the latest valued at $78.87 for each Shire share. The North Chicago, Ill.-based drug maker said discussions were no longer ongoing and offered no guarantee of another offer.
AbbVie’s proposal comes amid a wave of interest in such so-called tax inversion deals, most prominently Pfizer�� (PFE) failed $120 billion attempt to buy AstraZeneca (AZN). U.S. medical-device company Medtronic (MDT) on Sunday agreed to buy the U.K.‘s Covidien (COV) for $42.9 billion, also in part to lower its tax rate.
Buying Shire is about more than lowering AbbVie�� tax bill. The deal reduced Shire�� reliance on Humira sales before the patent protecting the arthritis drug expires in 2016.
But th
Top 10 Mid Cap Companies To Buy Right Now: Merck & Company Inc.(MRK)
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Advisors' Opinion:- [By Sean Williams]
Unfortunately, many cancers caused by smoking tend to be some of the most aggressive and virulent types, such as lung and pancreatic cancer. While medications do exist to treat lung cancer, the five-year prognosis is fairly grim, with a five-year survival rate of just 17%. This could be where Merck (NYSE: MRK ) or Bristol-Myers Squibb (NYSE: BMY ) swoops in to save the day.
Top 10 Mid Cap Companies To Buy Right Now: SBT Bancorp Inc (SBTB)
SBT Bancorp, Inc., incorporated on February 17, 2006, is the holding company for The Simsbury Bank & Trust Company, Inc. (the Bank). The Bank provides a variety of banking and investment services. The Bank has branch offices in the towns of Granby, Avon, and Bloomfield, Connecticut. The Bank also maintains a mortgage center in Canton, Connecticut. Services to the Bank�� customers are also provided through SBT Online Internet banking. The Bank's customer base consists primarily of individual consumers and small businesses in north central Connecticut. The Bank has in excess of 21,000 deposit accounts. In January 2011, the Bank formed Simsbury Bank Passive Investment Company, a subsidiary of Passive Investment Company (PIC).
During the year ended December 31, 2011, the Bank had seven automated teller machines (ATMs); two are located at each of its main office and its Bloomfield office, and one at each of the other branch/business offices. The Bank offers a range of commercial banking services to residents and businesses in its primary and secondary markets through a variety of commercial loans and residential mortgage programs, as well as home equity lines and loans, Federal Deposit Insurance Corporation (FDIC)-insured checking, savings, and individual retirement accounts (IRA), 401K rollover accounts, as well as safe deposit and other customary non-deposit banking services. The Bank offers investment products to customers through SBT Investment Services, Inc., a wholly owned subsidiary of the Bank, and through its affiliation with the securities broker/dealer LPL Financial Corporation.
Lending Activities
The Bank�� commercial loans are made for the purpose of providing working capital, financing the purchase of equipment, or for other business purposes. Such loans include loans with maturities ranging from thirty days to two years and term loans, which are loans with maturities normally ranging from 1 to 10 years. Short-term business loans are generally inten! ded to finance current transactions and typically provide for periodic principal payments, with interest payable monthly. Term loans normally provide for fixed or floating interest rates, with monthly payments of both principal and interest. The Bank�� construction loans are primarily interim loans made to finance the construction of commercial and single-family residential property. These loans are typically short-term. The Bank occasionally will make loans for speculative housing construction or for acquisition and development of raw land. Consumer loans are made for the purpose of financing automobiles, various types of consumer goods, and other personal purposes.
Investment Activities
As of December 31, 2011, the Bank�� investment portfolio consisted of the United States Government and agency securities, mortgage-backed securities, corporate bonds, municipal securities, and money market mutual funds. During 2011, proceeds from sales of available-for-sale securities amounted to $8,274,474.
Sources of Funds
Deposits are the Bank�� primary source of funds. At December 31, 2011, the Bank had a deposit mix of 43% checking, 34% savings, and 23% certificates of deposit. Thirty percent of the total deposits of $344.8 million were noninterest bearing at December 31, 2011. The Bank had brokered deposits of $9,017,198 as of December 31, 2011.
The Company competes with Bank of America, Webster Bank, People�� Bank, Windsor Federal Savings And Loan Association and Wells Fargo Bank.
Advisors' Opinion:- [By CRWE]
Today, SBTB remains (0.00%) +0.000 at $28.20 thus far (ref. google finance Delayed: 3:47PM EDT July 30, 2013).
SBT Bancorp, Inc., previously reported net income of $401,000 or $0.43 per diluted share for the second quarter of 2013, compared to $453,000 or $0.49 per diluted share for the second quarter of 2012.
For the six months ended June 30, 2013, net income amounted to $918,000, or $0.99 per diluted share. This compares to net income of $934,000 or $0.96 per diluted share for the six months ended June 30, 2012. Total assets on June 30, 2013 were $382 million compared to $340 million on June 30, 2012. 12
Top 10 Mid Cap Companies To Buy Right Now: Teekay Tankers Ltd(TNK)
Teekay Tankers Ltd., together with its subsidiaries, engages in the ownership and operation of oil tankers. As of August 16, 2011, it owned a fleet of nine double-hull Aframax tankers and six double-hull Suezmax tankers. The company, through its joint venture with Wah Kwong Maritime Transport Holdings Limited, also owned a very large crude carrier newbuilding. As of March 1, 2011, it operated four Aframax tankers in the Teekay Pool and three Suezmax tankers in the Gemini Pool arrangements; and five Aframax tankers and three Suezmax tankers under fixed-rate time-charter contracts. The company is headquartered in Hamilton, Bermuda.
Advisors' Opinion:- [By Sean Williams]
Tank you very much
I haven't been a fan of the shipping sector in years, but I'm finally coming around to a few of the stronger candidates. This week I plan to add oil transporter Teekay Tankers (NYSE: TNK ) to the list. - [By Taylor Muckerman]
After falling over 87% in the past five years, Teekay Tankers� (NYSE: TNK ) believes that the supply of carrying capacity is finally aligning itself with demand again. For 2014, the company expects the lowest fleet growth since 2002. If this is the case, management believes fleet utilization will have reached a trough and could possibly begin its ascent to levels north of 84%. Tankers haven't enjoyed this level of utilization since the industry sank below this depth in 2010.�
- [By Tim Melvin]
Teekay Tankers Ltd. (NYSE: TNK) is another cheap foreign stock to buy now that appears to have enormous recovery potential over the next few years.
Top 10 Mid Cap Companies To Buy Right Now: Quantum Energy Inc (QEGY)
Quantum Energy, Inc. (Quantum), incorporated on February 5, 2004, is engaged in the acquisition and exploration of oil and gas properties. As of February 28, 2010, the Company did not generate any revenues from its business operations.
The Company has acquired interests in oil and gas properties. The properties are located in the Barnett Shale area of West Texas.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap energy or mining stocks Yukon Gold Corporation (OTCMKTS: YGDC) and Quantum Energy Inc (OTCMKTS: QEGY) surged 323.5% and 41.2%, respectively, while 1st NRG Corp (OTCMKTS: FNRC) sank 25%. However, it should also be mentioned that two of these small cap stocks have been the subject of paid promotions. With that in mind, will these small cap energy or mining stocks deliver some more Christmas cheer this week? Here is a closer look and a reality check:
Top 10 Mid Cap Companies To Buy Right Now: Dollar Tree Inc.(DLTR)
Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise primarily at the fixed price of $1.00. The company operates its stores under the names of Dollar Tree, Deal$, Dollar Tree Deal$, Dollar Giant, and Dollar Bills. Its stores offer consumable merchandise, including candy and food, and health and beauty care, as well as household consumables, such as paper, plastics, household chemicals, in select stores, and frozen and refrigerated food; variety merchandise, which includes toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods, such as Easter, Halloween, and Christmas merchandise. As of April 30, 2011, it operated 4,089 stores in 48 states and the District of Columbia, as well as 88 stores in Canada. The company was founded in 1986 and is based in Chesapeake, Virginia.
Advisors' Opinion:- [By Jon C. Ogg]
Dollar Tree Inc. (NASDAQ: DLTR) was maintained as a Buy but was removed from the prized Conviction Buy list at Goldman Sachs.
Duke Energy Corp. (NYSE: DUK) was raised to Buy from Hold with a $79 price target at Argus.
- [By Nickey Friedman]
Dollar Tree (NASDAQ: DLTR ) continues to impress each quarter with robust sales, same-store sales growth, and diluted earnings-per-share increases. This dollar chain credits in large part a budget-conscious and cash-strapped consumer filling up its stores looking for bargains. Further growth seems like a no-brainer, but there are two things to watch for that could become speed bumps on its road to further riches.
No comments:
Post a Comment